Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented

Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT

Read more at globenewswire.com